|
|
|
|
|
Sponsors and Collaborators: |
Children's Oncology Group National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00002610 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors.
PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
Condition | Intervention | Phase |
Kidney Cancer |
Drug: carboplatin Drug: cyclophosphamide Drug: dactinomycin Drug: doxorubicin hydrochloride Drug: etoposide Drug: filgrastim Drug: vincristine sulfate Procedure: conventional surgery Procedure: radiation therapy |
Phase III |
MedlinePlus related topics: | Cancer Kidney Cancer Wilms' Tumor |
ChemIDplus related topics: | Doxorubicin Doxorubicin hydrochloride Cyclophosphamide Carboplatin Filgrastim Etoposide Vincristine sulfate Vincristine Etoposide phosphate Dactinomycin |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | NATIONAL WILMS TUMOR STUDY-5 -- TREATMENT OF RELAPSED PATIENTS |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of Wilms' tumor
Eligible subtypes:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Show 235 Study Locations |
Children's Oncology Group |
National Cancer Institute (NCI) |
Study Chair: | Daniel M. Green, MD | Roswell Park Cancer Institute |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000063900, COG-Q9402, NWTS-Q9402, CCG-4942, POG-9444, INT-0152, NWTS-5/R |
First Received: | November 1, 1999 |
Last Updated: | August 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00002610 |
Health Authority: | United States: Federal Government |
|
|
|
|
|